Cost-Effectiveness of Biomarker-Associated Early Pancreatic Cancer Detection in New-Onset Diabetes

What is the most cost-effective biomarker-associated pancreatic ductal adenocarcinoma (PDAC) screening strategy for individuals with new-onset diabetes?In this economic evaluation of early PDAC detection in new-onset diabetes, the sequential use of a type 3c diabetes (T3cD) biomarker test and a cancer-specific biomarker test approached cost-effectiveness (incremental cost-effectiveness ratio per quality-adjusted life-year of £34 223 [US $45 809]) compared with the current standard of care, where no routine screening is applied.This study suggests that, given the characteristics, particularly the specificity, of published biomarkers, screening of the high-risk group of individuals with new-onset diabetes for PDAC approaches cost-effectiveness when biomarker tests first enable enrichment for T3cD and then select for PDAC in this enriched group.

Corresponding Author: Eithne Costello, PhD, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Ashton Street, Liverpool L69 3GE, United Kingdom (ecostell@liverpool.ac.uk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.